- Home
- ACTU vs DHF Comparison
ACTU vs DHF Comparison
Compare ACTU & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACTU
- DHF
- Stock Information
- Founded
- ACTU 2015
- DHF 1998
- Country
- ACTU United States
- DHF United States
- Employees
- ACTU N/A
- DHF N/A
- Industry
- ACTU
- DHF Finance Companies
- Sector
- ACTU
- DHF Finance
- Exchange
- ACTU NYSE
- DHF Nasdaq
- Market Cap
- ACTU 154.3M
- DHF 183.3M
- IPO Year
- ACTU 2024
- DHF N/A
- Fundamental
- Price
- ACTU $6.96
- DHF $2.53
- Analyst Decision
- ACTU Strong Buy
- DHF
- Analyst Count
- ACTU 1
- DHF 0
- Target Price
- ACTU $20.00
- DHF N/A
- AVG Volume (30 Days)
- ACTU 36.4K
- DHF 451.1K
- Earning Date
- ACTU 05-21-2025
- DHF 01-01-0001
- Dividend Yield
- ACTU N/A
- DHF 7.65%
- EPS Growth
- ACTU N/A
- DHF N/A
- EPS
- ACTU N/A
- DHF N/A
- Revenue
- ACTU N/A
- DHF N/A
- Revenue This Year
- ACTU N/A
- DHF N/A
- Revenue Next Year
- ACTU N/A
- DHF N/A
- P/E Ratio
- ACTU N/A
- DHF N/A
- Revenue Growth
- ACTU N/A
- DHF N/A
- 52 Week Low
- ACTU $5.51
- DHF $2.06
- 52 Week High
- ACTU $11.73
- DHF $2.39
- Technical
- Relative Strength Index (RSI)
- ACTU N/A
- DHF 41.51
- Support Level
- ACTU N/A
- DHF $2.50
- Resistance Level
- ACTU N/A
- DHF $2.57
- Average True Range (ATR)
- ACTU 0.00
- DHF 0.03
- MACD
- ACTU 0.00
- DHF 0.00
- Stochastic Oscillator
- ACTU 0.00
- DHF 41.71
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. It invests predominantly in fixed-income securities of below-investment-grade credit quality.